In contrast, the monoclonal antibody AB0023 targeting LOXL2 demonstrates superior safety and efficacy: it simultaneously suppresses tumor metastasis and TGF-β signaling activation, showing broad applicability in both oncologic and fibrotic diseases 182. Here, LOXL2 is linked to neoplasm.